Carbylan Therapeutics - Articles and news items

Carbylan completes enrollment for its Phase 3 trial of Hydros-TA in osteoarthritis

Industry news / 9 June 2015 / Victoria White

Carbylan Therapeutics has completed enrollment of its COR1.1 Phase 3 pivotal trial of Hydros-TA for the treatment of pain associated with osteoarthritis…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+